Bellus hopes to fuel up on IPO cash as it squares off with giant Merck on a rival drug
Fueled by a successful Phase I trial treating chronic cough and lured by the promise of taking their lead drug to other applications, Montreal-based Bellus Health is looking to make its debut on Nasdaq with a $60 million IPO.
The public offering could be a major boon to the small Canadian company as it looks to outpace pharma giant Merck in the race to bring a P2X3-blocking drug to market. Blocking the P2X3 receptor is a closely studied method for reducing disorders around hypersensitivity, including most prominently chronic cough.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.